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ABSTRACT
Pancreatic cancer is the fourth leading cause of cancer death in the United States. 
Better understanding of pancreatic cancer biology may help identify new oncotargets 
towards more effective therapies. This study investigated the mechanistic actions of 
microRNA-1291 (miR-1291) in the suppression of pancreatic tumorigenesis. Our data 
showed that miR-1291 was downregulated in a set of clinical pancreatic carcinoma 
specimens and human pancreatic cancer cell lines. Restoration of miR-1291 expression 
inhibited pancreatic cancer cell proliferation, which was associated with cell cycle 
arrest and enhanced apoptosis. Furthermore, miR-1291 sharply suppressed the 
tumorigenicity of PANC-1 cells in mouse models. A proteomic profiling study revealed 
32 proteins altered over 2-fold in miR-1291-expressing PANC-1 cells that could be 
assembled into multiple critical pathways for cancer. Among them anterior gradient 2 
(AGR2) was reduced to the greatest degree. Through computational and experimental 
studies we further identified that forkhead box protein A2 (FOXA2), a transcription 
factor governing AGR2 expression, was a direct target of miR-1291. These results 
connect miR-1291 to the FOXA2-AGR2 regulatory pathway in the suppression of 
pancreatic cancer cell proliferation and tumorigenesis, providing new insight into 
the development of miRNA-based therapy to combat pancreatic cancer.
INTRODUCTION
Pancreatic adenocarcinoma is one of the most lethal 
malignancies in the world. It is the fourth most common 
cause of cancer-related deaths with a 5-year survival rate 
of 6%, and around 40,000 patients die from pancreatic 
cancer each year in the United States [1]. Pancreatic ductal 
adenocarcinoma (PDAC) is by far the most common type 
of pancreatic cancer and accounts for more than 85% of the 
different histologic subtypes of pancreatic cancer [2–4 ]. 
The mortality rate for pancreatic cancer remains high due 
to multiple factors including an inherently aggressive 
metastatic nature with early dissemination, a lack of 
reliable screening methods to make early diagnosis, and 
most importantly the lack of more effective therapies 
[1, 5–7 ]. One potential curative treatment for pancreatic 
cancer is surgical resection. However, less than 15% of 
patients have disease amenable to surgery at the time 
of diagnosis [8, 9] and median survival after surgical 
resection and adjuvant chemotherapy is only about 20–24 
months with 5 year survival rate of around 20% [10, 11]. 
Although our knowledge of pancreatic cancer biology is 
increasing, the causes of pancreatic cancer remain largely 
unknown and more effective therapies still await discovery 
and development. Therefore, identifying new targets and 
therapeutic strategy for patients with pancreatic carcinoma 
continues to be an urgent need.
MicroRNAs (miRs or miRNAs) are genome-derived 
noncoding RNA (ncRNA) molecules that govern target gene 
expression in cells in a sequence-specific manner [12–14]. 
Many miRNAs are revealed to play critical roles in the 
control of cancer cellular processes including proliferation, 
cell cycle, apoptosis, invasion, tumorigenesis and 
metastasis, which opens new avenues to develop miRNA-
based therapies. As an example, miR-34a replacement 
therapy has entered Phase I clinical trial for the treatment 
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of unresectable primary liver cancer [15, 16]. There are also 
some studies demonstrating that a number of miRNAs are 
aberrantly expressed in pancreatic cancer cells/tissues and 
involved in the regulation of many pancreatic cancer related 
genes [17–27]. Therefore, investigation of novel miRNA 
regulatory pathways may offer insights into identification 
of new pancreatic oncotargets and development of new 
therapeutics [7, 28, 29].
Our recent studies have identified that 
microRNA-1291 (miR-1291), a less studied miRNA 
that is generated from small nucleolar RNA H/ACA 
box 34 (SNORA34) in pancreatic cancer PANC-1 cells, 
is able to increase intracellular drug accumulation and 
chemosensitivity through targeting of efflux transporter 
namely multidrug resistance-associated protein 1 (MRP1/
ABCC1) [30, 31]. We have also demonstrated that miR-
1291 modulates the metabolome of PANC-1 cells and 
reduces cell migration and invasion capacity [32]. Other 
studies showed that miR-1291 is downregulated in clinical 
renal cell carcinoma specimens [33], and gain of miR-1291 
function inhibits the proliferation, migration and invasion of 
renal carcinoma A498 and 786-O cells [34]. 
The objective of the current study was to delineate the 
role of miR-1291 in pancreatic cancer. We first showed that 
miR-1291 was significantly downregulated in patient PDAC 
tissues, and restoration of miR-1291 expression/function 
inhibited pancreatic cancer cell proliferation in vitro through 
induction of G2/M cell cycle arrest and enhancement 
of apoptosis. Then we demonstrated miR-1291 sharply 
suppressed tumorigenicity of PANC-1 cells in xenograft 
mouse models in vivo. Proteomic profiling study revealed a 
set of proteins altered by miR-1291 that formed a network 
of interactions in the control of critical cancer properties. 
The most significantly downregulated protein was anterior 
gradient 2 (AGR2), which was conversely overexpressed 
in PDAC tissues. In addition, the transcription regulator of 
AGR2, forkhead box protein A2 (FOXA2) [35–37], was 
identified as a direct target of miR-1291. Together, our results 
link miR-1291 to FOXA2-AGR2 regulatory pathway in the 
suppression of pancreatic tumorigenesis. These findings 
improve the understanding of pancreatic miRNA oncotargets 
and provide insight that supports the development of miR-
1291-based therapy for the treatment of pancreatic cancer.
RESULTS
MiR-1291 expression is downregulated in human 
pancreatic cancer cell lines and patient tumor 
specimens
We first measured miR-1291 levels in human 
pancreatic cancer cell lines (PANC-1, AsPC-1, BXPC-3, 
and MIA PaCa-2) and compared to non-pancreatic cell lines 
including the hepatic cancer cell lines HepG2 and Huh7, 
colon carcinoma LS-180 cells, and cervical carcinoma 
Hela cells. The data showed that miR-1291 levels were 
remarkably lower in each of the four pancreatic cancer cell 
lines compared to the other cancer cell lines (Figure 1A). 
We then examined miR-1291 expression levels in patient 
PDAC tissues in comparison to normal pancreatic tissues. 
As shown in Figure 1B, miR-1291 levels were about 60% 
lower in PDAC tissues than unpaired non-tumor tissues. A 
more striking difference was seen in the five sets of paired 
specimens in which miR-1291 levels were 6-fold lower in 
tumor samples than their paired normal pancreatic tissues 
(Figure 1B). The decreased expression of miR-1291 found in 
human pancreatic cancer cell lines and PDAC tissues suggest 
that miR-1291 might be related to pancreatic tumorigenesis.
Restoration of miR-1291 expression reduces 
human pancreatic cancer cell proliferation by 
inducing G2/M cell cycle arrest and enhancing 
apoptosis
To delineate the potential role of miR-1291 in 
pancreatic cancer, we first investigate the effects of 
restoration of miR-1291 expression/function on pancreatic 
cancer cell proliferation. AsPC-1 and PANC-1 cells 
transiently transfected with miR-1291 expression plasmid 
exhibited about 50% lower viabilities, compared to cells 
transfected with empty vectors (data not shown). We 
thus generated stable miR-1291-expressing AsPC-1 and 
PANC-1 cells to explore potential mechanisms. Compared 
to corresponding controls, miR-1291-expressing PANC-1 
and AsPC-1 cells showed approximately 9- (Figure 2A) 
and 12-fold (Figure 2B) higher miR-1291 levels, which 
resulted in a significantly lower cell proliferation capacity 
(Figure 2C and 2D). Since PANC-1 cells were more 
sensitive to miR-1291 than AsPC-1 cells, PANC-1 cell 
lines were utilized for further studies.
To assess whether the inhibition of pancreatic cancer 
cell proliferation by miR-1291 involves mechanistic 
changes of cell cycle and apoptosis, we measured cell cycle 
(Figure 3A–3C) and apoptotic (Figure 3D–3F) profiles 
through flow cytometric analyses of propidium iodide and 
Annexin V/propidium iodide stained cells, respectively. Our 
data showed that restoration of miR-1291 expression led to a 
2-fold increase of PANC-1 cells in G2/M phase, which was 
accompanied by a significant reduction of cells in G1 phase 
and increase of cells in S phase (Figure 3A–3C). In addition, 
the fraction of early apoptotic cells was increased by 40% 
in miR-1291-expressing PANC-1 cells (Figure 3D–3F). 
Together, these results demonstrate that miR-1291 inhibits 
pancreatic cancer cell proliferation (Figure 2) via the 
induction of G2/M cell cycle arrest and enhancement of early 
apoptosis (Figure 3).
MiR-1291 suppresses the tumorigenicity of 
human pancreatic cancer cells in mouse models
To further define the impact of miR-1291 
on the tumorigenesis of pancreatic cancer cells, 
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miR-1291-expressing and control PANC-1 cells were 
injected subcutaneously into the right and left side of the 
dorsum of nude mouse, respectively, and outgrowth of 
xenograft tumors was monitored. The data revealed that 
growth of PANC-1 xenograft tumors in the same mouse 
was remarkably and significantly suppressed by miR-1291 
(Figure 4A and 4B). In addition, xenograft tumors derived 
from miR-1291-expressing PANC-1 cells were much 
smaller (Figure 4C) and over 10-fold lighter (Figure 4D) 
than the paired specimens generated from control PANC-1 
cells. These results indicate that miR-1291 is able to 
suppress the tumorigenicity of pancreatic cancer cells in 
xenograft mouse models.
MiR-1291 modulates the expression of many 
proteins in PANC-1 cells that are assembled into 
a network of tumor regulatory pathways 
To understand possible signaling pathways 
underlying miR-1291-controlled suppression of pancreatic 
tumorigenesis, an unbiased comprehensive proteomic 
profiling study was conducted to determine global protein 
Figure 1: miR-1291 expression levels are lower in human pancreatic cancer cell lines and patient PDAC tissues. (A) The 
expression levels of miR-1291 were remarkably lower in human pancreatic cancer cell lines than other cell lines. ***P < 0.001, compared 
to HepG2 cells. Values are mean ± SD (N = 3). (B) The average expression level of miR-1291 was about 60% lower in PDAC tissues than 
unpaired non-tumor tissues, and over 6-fold lower than paired peripheral non-tumor tissues.*P < 0.05, and**P < 0.01; values are mean ± SD.
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expression altered by miR-1291 (Figure 5). Our study 
using two-dimensional difference gel electrophoresis 
(2D-DIGE), matrix-assisted laser desorption/ionization 
(MALDI)-time of flight (TOF) and MS/MS analyses 
revealed 19 downregulated proteins and 13 upregulated 
proteins whose levels were altered over 2-fold in miR-
1291-expressing PANC-1 cells (Table 1, Figure 5A–5C). 
The pro-oncogenic protein AGR2 was revealed to be the 
one downregulated to the greatest degree (over 9-fold; 
Table 1), which was further confirmed by immunoblot 
(data not shown) and immunocytochemistry (Figure 5D 
and 5E). In addition, pathway analysis demonstrated 
that miR-1291-altered proteins formed a network of 
interactions in the modulation of many cancer cellular 
processes including cell proliferation, cell cycle arrest, 
invasion, endoplasmic reticulum stress, and energy 
metabolism (Figure 6). These results suggest that miR-
1291 modulates a network of important tumor-regulatory 
pathways in pancreatic cancer cells.
MiR-1291 is linked to FOXA2-AGR2 pathway in 
pancreatic cancer
Because AGR2 was down-regulated to the greatest 
extent in miR-1291-expressing PANC-1 cells and AGR2 
is a known proto-oncogene in the control of cancer cell 
proliferation, invasion and transformation [38–41], the 
clinical PDAC samples (Figure 1B) were thus employed 
to critically evaluate the relationship between miR-1291 
and AGR2. RT-qPCR analyses showed that AGR2 mRNA 
Figure 2: Restoration of miR-1291 expression suppresses the proliferation of PANC-1 and AsPC-1 cells. (A, B) miR-1291 
expression levels were about 9- and 12-fold higher in miR-1291 stably transfected PANC-1 and AsPc-1 cells, respectively, as compared to 
corresponding control cells transfected with empty vectors. (C, D) Cell proliferation capacity was significantly reduced in the miR-1291-
expressing PANC-1 and AsPC-1 cells, as determined by MTT assays. Viability of control cells at the last time point was set as 100%. Values 
are mean ± SD (N =3). ***P < 0.001, *P < 0.05, compared to control cells.
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Table 1: Proteins differentially expressed in miR-1291-expressing and control PANC-1 cells, 
which were identified by 2D-DIGE, MALDI-TOF and MS/MS proteomic profiling study
Fold of change 
Top Ranked Protein Name (Species) Gene(miR-1291/
control)
−9.49 Anterior gradient homolog 2 [Homo sapiens] AGR2 
−7.95 Argininosuccinate synthase [Homo sapiens] ASS1 
−4.03 Chain C, Structure Of The H3-H4 Chaperone Asf1Bound To Histones H3 And H4 ASF1
−2.77 Ornithine aminotransferase, mitochondrial isoform 1 precursor [Homo sapiens] OAT 
−2.50 Keratin, type II cytoskeletal 8 [Homo sapiens] KRT8 
−2.45 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) [Homo sapiens] PCK2 
−2.44
Chain A, The Crystal Structure Of Human Enoyl-Coenzyme A (Coa) Hydratase Short 
Chain 1, Echs1 ECHS1
−2.43 Phosphoserine aminotransferase isoform 1 [Homo sapiens] PSAT1
−2.41 Dihydrolipoamide acetyltransferase [Homo sapiens] DLAT
−2.39 Peroxiredoxin 3, isoform CRA_a [Homo sapiens] PRDX3
−2.39 Cysteine-rich protein 2 [Homo sapiens] CRIP2 
−2.32 Chain C, Human Pcna PCNA 
−2.20
Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus), isoform 
CRA a [Homo sapiens] FSCN1 
−2.19 Serpin H1 precursor [Homo sapiens] HSP47
−2.15 Protein disulfide-isomerase precursor [Homo sapiens] P4HB 
−2.15
Chain A, Crystal Structure Of The Protein-Disulfide Isomerase Related Chaperone 
Erp29 ERP29 
−2.15 Triosephosphate isomerase isoform 2 [Homo sapiens] TPI1 
−2.07 Peroxiredoxin-4 [Homo sapiens] PRDX4 
−2.00
Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial isoform a precursor 
[Homo sapiens] IDH3B 
2.39 Superoxide dismutase [Mn], mitochondrial isoform A precursor [Homo sapiens] SOD2 
3.49 Nicotinamide phosphoribosyltransferase precursor [Homo sapiens] NAMPT 
3.69 Chain B, Crystal Structures Of Native And Inhibited Forms Of Human Cathepsin D: Implications For Ly CTSD 
3.92 Chain A, Cellular Retinoic Acid Binding Protein Ii In Complex With A Synthetic Retinoic Acid (Ro-13) CRABP2 
5.10 Cofilin-1 [Homo sapiens] CFL1 
5.31 Elongation factor 2 [Homo sapiens] EEF2 
5.53 Protein mago nashi homolog [Homo sapiens] MAGOH 
6.58 UDP-glucose 6-dehydrogenase isoform 1 [Homo sapiens] UGDH 
6.60 Protein S100-A13 [Homo sapiens] S100A13 
6.97 Destrin isoform a [Homo sapiens] DSTN 
7.20 UDP-glucose 6-dehydrogenase isoform 1 [Homo sapiens] UGDH 
12.4 Keratin, type I cytoskeletal 19 [Homo sapiens] KRT19 
26.4 Chain A, Cellular Retinoic Acid Binding Protein Ii In Complex With A Synthetic Retinoic Acid (Ro-13) CRABP2 
The cut-off was 2-fold change.
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levels were over 2-fold and 20-fold higher in pancreatic 
tumor tissues than unpaired and paired non-tumor tissues 
(Figure 7A and 7B). Further immunohistochemistry 
analyses revealed a much greater level of AGR2 protein 
expression in PDAC tissues than adjunct normal 
pancreatic tissues (Figure 7C). The overexpression of 
AGR2 (Figure 7) and downregulation of miR-1291 
(Figure 1B) in pancreatic carcinoma indicates an inverse 
relationship between miR-1291 and AGR2 in pancreatic 
cancer.
Our efforts were thus directed to understand how 
miR-1291 might regulate AGR2 expression in pancreatic 
cancer cells. While bioinformatics analyses indicated that 
AGR2 did not appear to be a direct target of miR-1291, 
FOXA2, the transcription regulator of AGR2 [35–37], 
was predicted to be a potential target of miR-1291. Indeed 
the lower level of AGR2 protein expression in miR-1291-
expressing PANC-1 (Figure 8A) and AsPC-1 (Figure 8B) 
cells was associated with a reduced level of FOXA2 
protein expression. To evaluate the action of miR-1291 on 
the 3′UTR of FOXA2 consisting of two putative miRNA 
response elements (MREs) for miR-1291 (Figure 7C), we 
further constructed a FOXA2 3′UTR-luciferase reporter 
plasmid. Consequent luciferase reporter assays showed 
that gain and loss of miR-1291 expression/function was 
able to significantly reduce and increase FOXA2 3′UTR 
luciferase activities, respectively (Figure 8D and 8E), 
supporting that FOXA2 is a direct target of miR-1291. 
These results, along with the previous findings on the 
regulation of AGR2 by FOXA2 [35–37], demonstrate that 
miR-1291 modulates AGR2 expression via targeting of its 
transcription factor FOXA2.  
DISCUSSION
There are increasing number of studies 
demonstrating aberrant expression of miRNAs in a 
multitude of cancers and supporting the contribution 
of regulatory miRNAs to the initiation, progression, 
and metastasis of cancers. The current study revealed a 
significantly lower miR-1291 level in pancreatic tumor 
specimens as well as pancreatic cancer cell lines. Our 
data also demonstrated that re-introduction of miR-1291 
to pancreatic cancer cells remarkably suppressed 
tumorigenesis in xenograft mouse models, which might be 
attributable to the inhibition of cell proliferation, induction 
of G2/M cell cycle arrest, and enhancement of apoptosis. 
Furthermore, we identified a set of proteins altered in 
PANC-1 cells by miR-1291 that were assembled into 
critical tumor regulatory pathways. In addition, FOXA2 
was revealed as a direct target for miR-1291, which 
connected miR-1291 to the established FOXA2-AGR2 
Figure 3: Reintroduction of miR-1291 into PANC-1 cells induces a G2/M cell cycle arrest and an enhanced apoptosis. 
(A, B) Comparison of flow cytometry histograms of control and miR-1291-expressing PANC-1 cells stained with propidium iodide, and 
(C) the percentage of cells at various phases (G1/G0, S and G2/M). (D, E) Comparison of flow cytometry histograms of control and miR-
1291-expressing cells stained with Annexin V/propidium iodide, and (F) the percentage of apoptotic cells. Values are mean ± SD (N = 3). 
***P < 0.001,*P < 0.05, compared to corresponding controls. 
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regulatory pathway [35–37] in the control of pancreatic 
cancer cell properties.
MiR-1291 belongs to a special group of miRNAs 
that are derived from small nucleolar RNAs [30]. Recent 
studies have showed that miR-1291 level is lower in renal 
cell carcinoma specimens [33] and esophageal squamous 
cell carcinoma [42], and restoration of miR-1291 
suppresses renal and esophageal squamous cancer cell 
proliferation, migration and invasion [34, 42]. The present 
study is the first to find that miR-1291 is significantly 
downregulated in patient pancreatic carcinoma tissues 
and pancreatic cancer cell lines. Consistent with our 
recent findings on the antiproliferative activity of miR-
1291 [31], this study further demonstrated that restoration 
of miR-1291 expression/function significantly inhibited 
the growth of human pancreatic cancer cells, which was 
associated with an accumulation of cells in G2/M phase 
and larger fractions of apoptotic cells. In addition, miR-
1291 was revealed to largely suppress the tumorigenesis 
of PANC-1 cells, in which the same mouse was inoculated 
with both miR-1291-expressing and control PANC-1 cells. 
This study design is distinguished from our recent report 
that involves the use of different mice for xenograft tumor 
study [32], and current tumor mouse model not only 
allows the reduction of number of experimental animals 
for research but also minimizes interindividual variability 
and other confounding factors. Nevertheless, consistent 
results are obtained from present and previous studies 
[31, 32, 34, 42], indicating that miR-1291 acts as a tumor 
suppressor in renal, esophageal squamous, and pancreatic 
cancer cells.  
Several targets identified for miR-1291 thus 
far include the efflux transporter ABCC1 underlying 
multidrug resistance [30], the endoplasmic reticulum 
Figure 4: miR-1291 suppresses the tumorigenicity of PANC-1 cells in xenograft tumor mouse models. (A) Representative 
picture of mouse inoculated with control and miR-1291-expressing PANC-1 cells. (B) Growth of xenograft tumors from miR-1291-
expressing PANC-1 cells was significantly (P < 0.001, two-way ANOVA) slower than the control cells. **P < 0.01 and *P < 0.05, compared 
to the same time points. (C) Visual comparison of xenograft tumors excised from individual mice at week 8 after inoculation. (D) Xenograft 
tumors derived from miR-1291-expressing PANC-1 cells was significantly (***P < 0.001) lighter than the control cells. Values are mean 
± SD (N = 12). 
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Figure 5: Difference in global protein expression profiles between miR-1291-expressing and control PANC-1 cells. 
(A–C) 2D-DIGE images of proteins in the control and miR-1291-expression PANC-1 cells labeled with green and red fluorescent dye, 
respectively, and the overlaid graph indicating the difference in the abundance of proteins. The protein downregulated in miR-1291-
expressing PANC-1 cells to the greatest degree was identified as AGR2. (D, E) Immunocytochemistry analysis confirmed the sharp 
downregulation of AGR2 (brown staining) in miR-1291-expressing PANC-1 cells (400 ×). 
Figure 6: The network of interactions among miR-1291-modualted proteins. Network of interactions was constructed using 
IPA software. The input was all miR-1291-altered proteins (in bold) in PANC-1 cells identified by 2D-DIGE, MALDI-TOF and MS/MS 
proteomic profiling study.
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stress sensor IRE1α and consequently glypican-3 
(GPC3) implied in liver carcinogenesis [43, 44], glucose 
transporter protein type 1 (GLUT1/SLC2A1) critical for 
cell metabolism [34], and mucin 1 (MUC1) making up 
mucus [42]. Our recent metabolomics study have revealed 
nicotinamide N-methyltransferase (NNMT), an enzyme 
participating in nicotinate and nicotinamide metabolism, 
as a biomarker for miR-1291-altered pancreatic cancer cell 
metabolome [32]. The proteomics analysis in current study 
successfully identified a set of miR-1291-altered proteins 
that were assembled into multiple pathways important 
for cancer cellular processes including cell proliferation, 
cell cycle and apoptosis that were investigated in present 
study, as well as other cell functions such as fatty acid 
metabolism and gluconeogenesis. Although the connection 
between FOXA2-AGR2 signaling and nicotinate and 
nicotinamide metabolism is unknown, the disruption of 
fatty acid metabolism disclosed by metabolomics study 
[32] may be explained by the change of ECHS1 identified 
by present proteomics study. Most importantly, this study 
found that a series of cell metabolism-related proteins 
such as ASS1, OAT, UGDH, and PCK2 were significantly 
altered in miR-1291 expressing cells. Indeed, change of 
NNMT status was shown to alter the sensitivity of PANC-1 
cells to glucose deprivation and rapamycin as well as 
glycolytic inhibitor 2-deoxyglucose [45]. Rather, precise 
relationships between miR-1291 and these proteins in the 
control of specific cancer cellular processes need further 
investigation.
Oncogenic AGR2 was identified as the most 
significantly downregulated protein in miR-1291-
expressing PANC-1 cells with lower capacity in 
proliferation and tumorigenesis, consistent with previous 
findings on the critical role of AGR2 in pancreatic cancer 
[38, 40]. Indeed AGR2 is overexpressed throughout the 
progression to pancreatic cancer and has been shown to 
facilitate the initiation, progression, and dissemination of 
pancreatic cancer [38, 40, 46]. In addition, upregulation of 
AGR2 promotes the expression of MUC1 [46], which acts 
as an important regulator of the metabolism of pancreatic 
cancer cells [47]. A sharp reduction of AGR2 (current 
study) and significant change of cell metabolome [32] are 
unified for miR-1291-expression PANC-1 cells, suggesting 
that miR-1291 may be implicated in the metabolism of 
pancreatic cancer cells. Consistent with previous studies, 
our findings support the notion that AGR2 represents a 
druggable oncotarget for the development of new therapies 
to treat notoriously lethal pancreatic cancer.
Although many genes encoding those altered 
proteins in miR-1291-expressing PANC-1 cells do not 
seem to be directly regulated by miR-1291, the present 
study identified FOXA2 as a direct target for miR-1291. 
Luciferase assays supported the interaction of miR-
1291 with FOXA2 3′UTR consisting of miR-1291 MRE 
sites predicted by bioinformatic analysis. Furthermore, 
consistent with the results obtained from miR-1291-
expressing pancreatic cancer cells (this study), both 
FOXA2 and AGR2 protein levels were reduced in cells 
after transient transfection with miR-1291 expression 
plasmids (data not shown) or bioengineered miR-
1291 agent [31]. While further biological experiments 
are necessary to validate FOXA2 as a direct target of 
Figure 7: AGR2 is overexpressed in patient PDAC tissues, which is in contrast to the reduced expression of miR-1291 
(Figure 1B). (A, B) AGR2 mRNA levels were significantly higher in pancreatic tumor tissues than non-tumor tissues, as determined 
by selective qPCR analyses. (C) AGR2 protein (brown stains) levels were much higher in patient PDAC than adjunct normal pancreatic 
tissues, as demonstrated by immunohistochemistry study. 
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miR-1291, this study has firmly established the impact 
of miR-1291 on FOXA2. Most importantly, FOXA2 is a 
member of the fork head transcription factor family that 
binds to the promoter region of AGR2 and activates the 
transcription of AGR2 [35–37]. FOXA2 is also essential 
for cell differentiation, metabolism, and maturation 
including pancreas development and epithelial-to-
mesenchymal transition [48, 49]. Therefore, current study 
unveiled the connection between miR-1291 and FOXA2-
AGR2, namely miR-1291-FOXA2-AGR2 pathway, in the 
modulation of pancreatic cancer cellular processes.
It is possible that other genes and pathways might 
be also involved in miR-1291-caused downregulation 
of AGR2 (as well as changes of other proteins listed in 
Table 1) in suppressing the proliferation and tumorigenesis 
of pancreatic cancer cells. Actually AGR2 protein 
levels were reduced to different degrees in miR-1291-
expressing PANC-1 and AsPC-1 cells, highlighting 
intrinsic difference in the regulatory pathways beyond 
miR-1291-FOXA2-AGR2 between the two cells lines. 
In addition, the extent of decrease in AGR2 protein 
levels was greater than that of FOXA2 in miR-1291-
expressing PANC-1 cells, suggesting the presence of other 
pathways and an accumulative effect on the suppression 
of AGR2 expression. Besides FOXA2, several other 
cancer-related genes such as protein kinase B AKT2 
[50–52] and methyl-CpG binding protein 2 (MeCP2) 
[53–55] were also identified as putative targets for miR-
1291 by computational analysis. The protein levels of 
AKT2 and MeCP2 were indeed reduced in miR-129-
Figure 8: miR-1291 modulates AGR2 expression through targeting of FOXA2, a known transcriptional regulator 
of AGR2. (A, B) Western blot analysis showed that both FOXA2 and AGR2 protein levels were much lower in miR-1291-expressing 
PANC-1 (A) and AsPC-1 (B) cells, as compared to corresponding control cells. GAPDH was used as a loading control. (C) Computational 
analysis revealed two putative MRE sites for miR-1291 within the 3′UTR of FOXA2. Underlined is the seed sequence of miR-1291. 
(D, E) FOXA2 3′UTR luciferase reporter activities were decreased in PANC-1 cells (D) and increased in HepG2 cells (E) after the transfection 
with miR-1291 expression plasmid and antagomir, respectively.*P < 0.05, compared to the control group. Values are mean ± SD (N = 9). 
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expressing PANC-1 cells (unpublished data) or MCF-7 
cells transiently transfected with miR-1291 agent [31]. 
Therefore, further studies on additional targets of miR-
1291 are necessary to provide an improved mechanistic 
understanding of miR-1291 pathways in the regulation of 
pancreatic cancer processes.
In conclusion, the present study revealed a miR-
1291-FOXA2-AGR2 signaling pathway behind miR-
1291-controlled suppression of pancreatic tumorigenesis. 
Our results demonstrated that miR-1291 was significantly 
downregulated in pancreatic cancer specimens, which 
was in contrast to the overexpression of oncogenic 
AGR2. Furthermore, restoration of miR-1291 expression 
inhibited pancreatic cancer cell proliferation that was 
attributed to the induction of G2/M cell cycle arrest and 
apoptosis. These findings improve our understanding of 
pancreatic cancer and critical regulatory pathways which 
provide insight into the development of miR-1291-based 
therapeutic strategy.
MATERIALS AND METHODS 
De-identified patient samples
The de-identified pancreatic cancer patient samples 
and non-tumor tissues were obtained from the Pathology 
Resource Network of Roswell Park Cancer Institute 
(RPCI). All samples were processed according to the 
standard pathology procedures at the RPCI including 
quality control and verification by pathologist. A total of 
22 tissue specimens from non-Spanish, White patients 
were used for this study, among which 7 donors are 
females and 15 donors are males. The ages of patients 
were between 31 and 84 years at enrollments, with a mean 
value of 63.3 and standard deviation (SD) of 13.6. Samples 
were subjected to biochemical and immunohistochemistry 
analyses under the protocol NHR 022611 approved by the 
Office of Research Subject Protection at RPCI.
Plasmids
The coding sequence of FOXA2 (NM_021784.4) 
3′UTR segment (0–830 bp from stop codon) consisting 
of miR-1291 MRE sites that were predicted by 
TargetScan (http://www.targetscan.org/) was amplified 
from human genome by PCR using gene specific 
primers, 5′-CCG CTC GAG GGG GTG TAC TCC CGG 
CCC ATT ATG AAC TCC TCT-3′ (forward) and 5′-TTG 
CGG CCG CGG GCC AAA ATA AAA TAC AAC CTG 
CAA CCA GAC A-3′ (reverse), and cloned downstream 
of Renilla luciferase gene within psiCHECK-2 vector 
after digested with XhoI and NotI. The FOXA2 3′UTR-
luciferase reporter plasmid was confirmed by direct DNA 
sequencing and named as psiCHECK-FOXA2–3 ′UTR. 
The miR-1291 expression plasmid and the control empty 
vector were described recently [30].
Cell culture
Human pancreatic cancer cell lines PANC-1, AsPC-1, 
MIA PaCa-2, BXPC-3, liver cancer HepG2 cells, colon 
carcinoma LS-180 cells, and cervical carcinoma HeLa 
cells were purchased from ATCC (Manassas, VA), and 
human hepatocellular carcinoma Huh-7 cells were bought 
from Riken Cell Bank (Wako, Saitama, Japan). All cells 
were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) or Eagle’s Minimum Essential Medium 
(EMEM) containing 10% FBS, 100 U/ml of penicillin 
sodium, and 100 µg/ml of streptomycin sulfate at 37°C 
in a humidified atmosphere of 5% CO2. The miR-1291-
expressing and control PANC-1 cells were established 
recently in our lab [30]. AsPC-1 cells stably transfected 
with miR-1291 expression plasmid and empty control 
vector were developed in the same manner.
Cell viability
Cells were seeded in 24-well plates at a density of 
4 × 103 (AsPC-1 cells) or 5 × 103 (PANC-1 cells), and cell 
viability was evaluated at various time points (24, 72, and 
144 h) using MTT assay, as described [56].
Cell cycle and apoptosis analyses
Percentages of apoptotic cells and cell cycle phases 
were determined using a FACSCalibur flow cytometer 
(BD Biosciences, San Jose, CA) after the cells were 
stained with Annexin-V FITC Apoptosis Kit (Invitrogen, 
Carlsbad, CA) and propidium iodide/RNase (Sigma-
Aldrich, St. Louis, MO), respectively, as we described 
recently [56]. All experiments were carried out in triplicate 
with separate cultures and all data were analyzed with 
Flowjo (Ashland, OR). 
2D-DIGE and proteomics study
Proteins were extracted from miR-1291-expressing 
PANC-1 cells and control cells, and subjected to 
2D-DIGE and protein identification by MALDI-TOF 
and tandem MS (Applied Biomics, Hayward, CA), as 
described [57, 58]. Briefly, equal amounts of Cy3- and 
Cy5-labeled cellular proteins (50 μg each) were separated 
by 2D-DIGE, and the 2D gel images were acquired 
using a Typhoon Trio scanner (Amersham BioSciences, 
Piscataway, NJ). Scanned images were analyzed by 
Image Quant software (Amersham BioSciences), and 
a complete analysis of all differentially expressed 
proteins was obtained from the 2D-DIGE-derived data 
using Decyder software (Amersham BioSciences). Spots 
with differential expression and a consistent presence 
in replicate gels were identified and obtained using the 
Ettan Spot Picker. After the staining dye was removed, 
the samples were dried, rehydrated and digested in-gel 
at 370C overnight. Digested samples were extracted, 
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desalted, mixed with α-cyano-4-hydroxycinnamic acid 
matrix and subjected to MALDI-TOF MS/MS analysis 
(Applied Biosystems 4700 Proteomics Analyzer, 
Applied Biosystems, Foster City, CA). Identification 
of each protein spot was performed by analyzing the 
peptide fingerprinting MS and fragmentation MS/MS 
spectra, which were submitted for database search using 
GPS Explorer software (Applied Biosystems, Foster 
City, CA) equipped with the MASCOT search engine. 
The highest scoring hit with a protein score confidence 
interval more than 95% was accepted as positive protein 
identification for that spot.
Pathway analysis
Proteins identified above that were altered in PANC-1 
cells by miR-1291 were mapped into molecular networks 
using Ingenuity Pathway Analysis (IPA) (www.ingenuity.
com), based on the gene’s functional annotation and 
molecular interactions, and searched for over-represented 
signaling and metabolic canonical pathways and diseases.
Luciferase report assay
The luciferase assay was performed as described 
previously [30, 59]. Briefly, PANC-1 cells were co-
transfected with FOXA2 3′UTR luciferase reporter 
plasmid and miR-1291 expression or control plasmid. 
HepG2 cells were co-transfected with FOXA2 3′UTR 
luciferase expression plasmid and 50 nM miR-1291 
antagomir or control oligonucleotides. Luciferase 
activities were determined using dual-luciferase reporter 
assay system (Promega, Madison, WI) and a Berthold 
Centro LB 960 luminometer (Berthold Technologies, 
Oak Ridge, TN). Relative luciferase activities were 
calculated as the ratio between Renilla luciferase and 
firefly luciferase and further normalized to corresponding 
controls. 
RNA isolation and reverse transcription 
quantitative real-time (RT-qPCR) analysis
Total RNAs were isolated from patient samples 
and human cells with Trizol reagent, and quantified using 
a NanoDrop spectrophotometer (Thermo Scientific, 
Rockford, IL). Regular and stem-loop reverse transcription 
of mature miR-1291 were conducted as described 
previously [30, 60]. RT-qPCR was performed on a MyIQ 
real-time PCR system (Bio-Rad, Hercules, CA). The cycle 
number (CT) at which the amplicon concentration crossed 
a defined threshold was determined for each individual 
miRNA. The relative level of each analyte over internal 
standard (glyceraldehyde-3-phosphate dehydrogenase, or 
U6) was calculated as 2-ΔΔCT, where ΔΔCT = ΔCT treatment group 
(analyte – internal standard) – ΔCT control group (analyte – 
internal standard).
Western blot 
Cells were lysed in RIPA buffer (Rockland 
Immunochemical Inc., Limerick, PA) supplemented 
with complete protease inhibitors (Roche, Nutley, NJ), 
and protein concentrations were determined using a 
BCA Protein Assay Kit (Thermo Fisher Scientific Inc.). 
Proteins (50 µg per lane) were separated on a 10% SDS-
PAGE gel and then transferred onto ECL membranes (GE 
Healthcare, Piscataway, NJ). Membranes were incubated 
with primary antibodies against AGR2 (1/10,000 dilution; 
Abcam, Cambridge, MA), FOXA2 (1/2,000 dilution; 
Abcam), or GAPDH (1/2,000 dilution, Santa Cruz Biotech 
Inc., Texas, TX), and then with a HRP labeled anti-mouse 
IgG secondary antibody (Jackson ImmunoResearch 
Inc., West Grove, PA). The membranes were incubated 
with ECL substrates for 1 min, and target proteins were 
visualized with a ChemiDoc XRS Imaging System (Bio-
Rad, Hercules, CA). 
Immunohistochemistry and 
immunocytochemistry analysis 
The expression of AGR2 in PANC-1 cells and PDAC 
patient tissues was determined by immunocytochemistry 
and immunohistochemistry as described before [38, 40] 
with modifications. Briefly, staining was done on 5-μm 
thick paraffin sections using rabbit anti-AGR2 antibody 
(Abcam, ab76473, 1:30 dilution), following protocols 
for the DAKO Autostainer Link 48 System. Images were 
captured using an Olympus camera (DP25) and CellSens 
software (Olympus, Center Valley, PA). 
Xenograft tumor study
All animal studies were conducted in accordance 
with National Institutes of Health animal use guidelines 
and the protocol approved by the Institutional Animal Care 
and Use Committee at SUNY-Buffalo. Athymic male nude 
(CD-1 nu/nu) mice (8 weeks old) were purchased from 
The Jackson Laboratory (Bar Harbor, ME). Exponentially 
growing control and miR-1291-expressing PANC-1 
cells were harvested, resuspended in 100 μL of PBS/
Matrigel (1:1) solution and injected subcutaneously (10 
million cells/animal) into nude mice (12 per group). 
Tumor size was measured once per week for 8 weeks 
and tumor volume was calculated using the formula, 
tumor volume = 0.5 × length × width2. Mice were 
euthanized at the end of the study, and tumors were 
collected, weighted and subjected to the pathohistological 
analyses.
Statistical analysis
All values are expressed as mean ± S.D. Different 
treatments (qPCR, luciferase data and tumor size) were 
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compared by unpaired Student’s t-test, one-way or two-
way ANOVA with Bonferroni post-tests (Prism, GraphPad 
Software Inc., San Diego, CA). Difference was considered 
as significant if the probability was less than 0.05 (P < 0.05).
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